CBC Group's $21B healthcare mega-merger lifts Everest Medicines bet
What's the deal? CBC GroupDealroom has a profile for this one. Try Dealroom →, a major shareholder in Hong Kong-listed Everest Medicines, bought 600,500 shares of the company between May 20 and May 21 for roughly HK$19.2M ($2.5M). The purchase is part of a broader buying spree: since December 2025, CBC Group and Everest's directors have snapped up more than 3 million shares worth over HK$113.8M.
The share purchases coincide with CBC Group's announced merger with GHO CapitalDealroom has a profile for this one. Try Dealroom →, a European healthcare-focused investment firm. The 50:50 deal is expected to close in early 2027, creating a platform managing more than $21B in assets — potentially the world's largest healthcare-focused investment manager.
Why now? Everest Medicines is on a tear. It reported 142% year-over-year revenue growth in 2025, driven by its core product NEFECON, which generated RMB 1.443B in sales — a more than 300% jump. The company has laid out an ambitious 2030 strategy targeting revenue above RMB 15B and a portfolio of more than 20 commercialised products.
The CBC-GHO merger would give Everest a shareholder with reach across North America, Europe, and Asia-Pacific — regions that account for roughly 90% of global healthcare R&D investment. That footprint could help accelerate the company's push to become a global biopharmaceutical player.
What could go wrong? Mega-mergers in investment management are notoriously difficult to integrate. A 50:50 structure can create governance friction, and the deal still needs to close. Meanwhile, Everest's aggressive growth targets depend on sustained commercial execution and successful international expansion — neither of which is guaranteed.
CBC Group and the directors have signalled they may buy more shares, but such insider confidence doesn't always translate into market returns.
The signal: CBC Group and GHO Capital are both classified as investment funds on Dealroom, and their merger underscores a consolidation wave among specialist healthcare investors seeking global scale. With dedicated healthcare funds bulking up, portfolio companies like Everest Medicines stand to benefit from deeper pockets and wider networks — but the trend also raises the stakes for returns, as larger platforms face pressure to deploy ever-bigger cheques into an increasingly competitive biopharma landscape.
Read more: acnnewswire.com
